Open Access
Med Sci (Paris)
Volume 35, Number 10, Octobre 2019
Page(s) 728 - 731
Section Le Magazine
Published online 18 October 2019
  1. Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science 2017 ;355 :1152–1158. [Google Scholar]
  2. Postel-Vinay S, Bajrami I, Friboulet L, et al. A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer. Oncogene 2013 ;32 :5377–5387. [Google Scholar]
  3. Ferrara R, Mezquita L, Texier M, et al. Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncol 2018 ;4 :1543–1552. [CrossRef] [PubMed] [Google Scholar]
  4. Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 2018 ;378 :2078–2092. [Google Scholar]
  5. Chabanon RM, Pedrero M, Lefebvre C, et al. Mutational landscape and sensitivity to immune checkpoint blockers. Clin Cancer Res 2016 ;22 :4309–4321. [CrossRef] [PubMed] [Google Scholar]
  6. Parkes EE, Walker SM, Taggart LE, et al. Activation of STING-dependent innate immune signaling by S-phase-specific DNA damage in breast cancer. J Natl Cancer Inst 2017 ;109. [Google Scholar]
  7. Chabanon RM, Muirhead G, Krastev DB, et al. PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer. J Clin Invest 2019 ;129 :1211–1228. [CrossRef] [PubMed] [Google Scholar]
  8. Harding SM, Benci JL, Irianto J, et al. Mitotic progression following DNA damage enables pattern recognition within micronuclei. Nature 2017 ;548 :466–470. [CrossRef] [PubMed] [Google Scholar]
  9. Ding L, Kim HJ, Wang Q, et al. PARP Inhibition elicits STING-dependent antitumor immunity in Brca1-deficient ovarian cancer. Cell Rep 2018 ;25(2972–80) :e5. [Google Scholar]
  10. Shen J, Zhao W, Ju Z, et al. PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness. Cancer Res 2019 ;79 :311–319. [Google Scholar]
  11. Sen T, Rodriguez BL, Chen L, et al. Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer. Cancer Discov 2019 ;9 :646–661. [CrossRef] [PubMed] [Google Scholar]
  12. Pantelidou C, Sonzogni O, De Oliveria Taveira M, et al. PARP inhibitor efficacy depends on CD8+ T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer. Cancer Discov 2019 ;9 :722–737. [CrossRef] [PubMed] [Google Scholar]
  13. Chanut R, Petrilli V. Détection de l’ADN cytosolique par la voie cGAS-STING : de l’immunité innée vers le contrôle de la tumorigenèse. Med Sci (Paris) 2019 ;35 :527–534. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.